Ignace Billiet
Papers
1
Total Citations
459
H-Index
1
About
Ignace Billiet is a leading figure in prostate cancer outcomes research, best known for his pivotal contributions to evidence-based treatment comparisons. His landmark 2012 study, "Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy," has amassed over 450 citations, underscoring its foundational role in the field. This work systematically evaluated treatment effectiveness using prostate-specific antigen (PSA) as the most sensitive endpoint, addressing a critical gap in comparative effectiveness research. Billiet’s research focuses on risk-stratified outcomes for prostate cancer therapies, helping clinicians and patients navigate treatment decisions for low, intermediate, and high-risk disease. His findings have shaped clinical guidelines by providing robust, comparative data on radical therapy results. Beyond this seminal paper, Billiet’s work continues to influence urologic oncology, emphasizing the importance of standardized metrics like PSA-free survival. His contributions have not only advanced scientific understanding but also improved patient counseling and treatment planning, making him a respected voice in prostate cancer research.
Research Focus
Key Achievements
Top Papers
- 1